Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,349,099
  • Shares Outstanding, K 44,940
  • Annual Sales, $ 6,050 K
  • Annual Income, $ -97,180 K
  • 36-Month Beta 4.94
  • Price/Sales 105.76
  • Price/Cash Flow N/A
  • Price/Book 7.58

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.07 +24.72%
on 12/18/17
36.00 -16.61%
on 01/03/18
+5.02 (+20.08%)
since 12/15/17
3-Month
20.29 +47.95%
on 11/08/17
36.00 -16.61%
on 01/03/18
+7.23 (+31.72%)
since 10/16/17
52-Week
13.12 +128.81%
on 05/31/17
36.00 -16.61%
on 01/03/18
+11.26 (+60.02%)
since 01/13/17

Most Recent Stories

More News
Stock Review for Biotech's Investors -- Editas Medicine, Illumina, Tesaro, and Endocyte

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EDIT, ILMN, TSRO, and ECYT which can be accessed for free by signing up to www.wallstequities.com/registration....

ILMN : 241.42 (-1.35%)
ECYT : 3.80 (-6.40%)
EDIT : 30.02 (-6.19%)
TSRO : 65.52 (-5.85%)
Editas Medicine Reports on Recent Progress and Announces "EM22" Five-year Goals at J.P. Morgan Healthcare Conference

By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials

JPM : 112.27 (-0.36%)
EDIT : 30.02 (-6.19%)
Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36 Annual J.P. Morgan Healthcare...

JPM : 112.27 (-0.36%)
EDIT : 30.02 (-6.19%)
NASDAQ Passes 7,000 to Start 2018

NASDAQ Passes 7,000 to Start 2018

LUK : 27.55 (-1.36%)
HFC : 52.25 (-0.50%)
CI : 214.75 (+0.64%)
LYV : 43.66 (-1.73%)
VRTX : 155.71 (-1.41%)
IAC : 132.77 (-1.43%)
SEMG : 29.00 (-0.85%)
EDIT : 30.02 (-6.19%)
SNE : 48.95 (-2.16%)
TRCO : 43.47 (+0.28%)
WMB : 32.59 (-1.87%)
CTRP : 48.22 (+1.17%)
NOV : 38.47 (-1.71%)
PBF : 34.53 (-1.68%)
YELP : 43.58 (-3.99%)
KBR : 20.21 (-1.85%)
UNFI : 47.80 (+0.80%)
SFM : 25.75 (+1.10%)
NCS : 18.55 (-1.85%)
Mass Innovation Labs Announces Expansion to NB Development Group's Boston Landing

Mass Innovation Labs, the world's leading accelerated commercialization program for the biopharmaceutical industry, today announced a major expansion into the hardware and technology...

EDIT : 30.02 (-6.19%)
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for...

EDIT : 30.02 (-6.19%)
Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common stock. The gross proceeds to Editas Medicine...

MS : 54.60 (-0.94%)
EDIT : 30.02 (-6.19%)
Editas Medicine, Inc., Announces Offering of Common Stock

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell $50,000,000 of shares of its common stock in an underwritten public offering. Editas...

MS : 54.60 (-0.94%)
EDIT : 30.02 (-6.19%)
Bitcoin or CRISPR: Which is the Bigger Disruptor?

In just 5 years, two new "exponential technologies" have been created that will dramatically change the world

NVDA : 220.11 (-1.29%)
CRSP : 27.18 (-4.70%)
JPM : 112.27 (-0.36%)
EDIT : 30.02 (-6.19%)
CME : 152.20 (-0.35%)
MGTI : 3.6400 (-12.81%)
AMZN : 1,304.86 (-0.03%)
Don't Fight the Gravity of Exponential Change

Technology is reshaping life and business so fast that intelligent adaptation could be the #1 skill of the 21st century.

NVDA : 220.11 (-1.29%)
AAPL : 176.19 (-0.51%)
CRSP : 27.18 (-4.70%)
CYBR : 42.39 (-2.37%)
EDIT : 30.02 (-6.19%)
FEYE : 15.03 (-3.59%)
SWKS : 99.86 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 34.66
1st Resistance Point 32.34
Last Price 30.02
1st Support Level 28.36
2nd Support Level 26.70

See More

52-Week High 36.00
Last Price 30.02
Fibonacci 61.8% 27.26
Fibonacci 50% 24.56
Fibonacci 38.2% 21.86
52-Week Low 13.12

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.